Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Weifuchun Tablet in Reversing Gastric Intestinal Metaplasia: A Multi-center, Open-label, Randomized Controlled Trial

NCT06610266 is registered in ClinicalTrials.gov with Yongquan Shi as lead sponsor.

NCT NCT06610266
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06610266 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Weifuchun Tablet in Reversing Gastric Intestinal Metaplasia: A Multi-center, Open-label, Randomized Controlled Trial
Lead sponsor
Yongquan Shi
Phase
Phase 4
Overall status
Recruiting
Start date
February 28, 2025
Completion date
December 31, 2027
Enrollment
400 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

gastric intestinal metaplasia